Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Leukemia|July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202Amy S Ruppert, Allison M Booth, Wei Ding, et al.Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemiaSusan O'Brien, Gary Schiller, John Lister, et al.Journal of Oncology Practice|July 21, 2017
Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic CenterJulie Bryar Porter, Eben Lloyd Rosenthal, Marcy Winget, et al.Blood|January 14, 2017
Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraSimon Mantha, Debra A Goldman, Sean M Devlin, et al.Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.Blood|May 13, 2004
Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT TrialJeffrey McCullough, David H Vesole, Richard J Benjamin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Haematologica|July 29, 2017
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trialsJennifer R Brown, Javid Moslehi, Susan O'Brien, et al.Pageof 5